In order to verify the ability of HJB in human leukemia therapies, the effect of HJB on the HL60 cell line that represent a human promyelocytic leukemia cells BCR/ABL negative cells (acute myeloid leukemia) was investigated. This evidence concerns the gene BCR and acute promyelocytic leukemia.